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Incidence and clinical characteristics of multiple
myeloma with low M-protein levels and normal
values of hemoglobin, creatinine, calcium, and
serum free light chain ratio
Agoston Gyula Szabo 1, Tobias Wirenfeldt Klausen2, Niels Abildgaard3, Henrik Gregersen4, Trine Silkjær5,
Per Trøllund Pedersen6, Robert Schou Pedersen7, Carsten Helleberg2, Emil Hermansen 8, Brian Iversen Schnack1 and
Annette Juul Vangsted 9
Dear Editor,
The presence of an M-protein in the serum is a com-
mon incidental finding. It can be associated with infec-
tions, inflammatory conditions and autoimmune diseases,
and the asymptomatic precursor conditions monoclonal
gammopathy of undetermined significance (MGUS) and
smoldering multiple myeloma (SMM). Only one percent
of individuals with MGUS progress to a malignant plasma
cell or lymphoproliferative disease per year1,2 and an
important predictor of progression is the level of the M-
protein at the time of diagnosis, which is used in the risk-
stratification model by the Mayo Clinic2–4. Early diagnosis
and treatment of multiple myeloma (MM) is important, as
delays may result in life-threatening infections, painful
bone fractures, or dialysis-dependent renal failure5–9.
Moreover, there is increasing evidence supporting treat-
ment of patients with SMM and this question is being
explored in several ongoing clinical trials10. The serum
free light chain (sFLC) assay, imaging of the skeleton, a
bone marrow biopsy, and blood tests are part of the
diagnostic work-up for MM, but if clinical evaluation and
blood tests suggest low risk MGUS, a baseline bone
marrow examination and skeletal radiography are not
recommended by the International Myeloma Working
Group3,11.
In a recently published retrospective review from the
Mayo Clinic, Sidiqi et al. reported that 29 (1.3%) of 2225
MM patients had laboratory values within reference range
for calcium, creatinine, hemoglobin, a sFLC ratio <100,
and absence of lytic lesions assessed by conventional
skeletal survey. These patients would have been mis-
classified as SMM or MGUS without bone marrow biopsy
or advanced imaging12.
The aim of our study was to describe the incidence of
MM and SMM with an MGUS-like profile (defined as
MM with IgG M-protein ≤ 1.5 g/dl or an IgA M-protein
≤ 1.0 g/dl and with normal levels of ionized calcium,
creatinine, and hemoglobin) since 2005 in Denmark.
Furthermore, we wanted to characterize the patients with
MGUS-like MM who also had a normal sFLC ratio at
diagnosis. Finally, we wanted to understand the reasons
for referral for diagnostic work-up for these MM patients
with no apparent signs of organ damage.
We used the population-based Danish Multiple Mye-
loma Registry (DMMR), which includes clinical data for
all patients with MM and SMM diagnosed since 200513–15.
Measurements of sFLC have been recorded in the DMMR
since 2012. A sFLC ratio of 0.26–1.65 at diagnosis was
defined as normal. Patients with LDH levels above normal
were standardized according to age. In patients with age
>70 years the upper limit was ≥255 UL, and in patients
with age ≤70 the upper limit was ≥205 UL. Hypo-
gammaglobulinemia was defined qualitatively as one or
more of uninvolved immunoglobulins below normal
levels (IgG < 6.1 g/L, IgA < 0.70 g/L, IgM < 0.39 g/L).
High-risk cytogenetics were defined as the presence of
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Fig. 1 Flow-chart for study inclusion and the incidence of multiple myeloma in Denmark. A Flow-chart for study inclusion: Among 5116
patients diagnosed with MM or SMM and registered in the DMMR, a diagnostic sFLC result was available in 2515 patients and 785 had a normal sFLC
ratio. Of these patients, 139 had an MGUS-like phenotype IgG M-protein ≤1.5 g/dl or an IgA M-protein ≤1.0 g/dl and with normal levels of normal
hemoglobin, creatinine, ionized calcium and no amyloidosis, medullary compression syndrome, extramedullary myeloma, peripheral neuropathy or
dialysis-dependent renal failure at presentation. MM multiple myeloma, SMM smoldering myeloma, sFLC serum free light chain. B Incidence of
multiple myeloma in Denmark: The columns with values displayed on the left vertical axis show the incidence of multiple myeloma pr. 100.000 in
Denmark, age adjusted to the EU 2013 standard population. Filled circles present the age-adjusted incidence for all MM patients and the filled
triangles present the age-adjusted incidence of myeloma patients with an IgG M-protein ≤1.5 g/dL and IgA M-protein ≤1.0 g/dL and normal blood
levels of ionized calcium, creatinine, and hemoglobin. The gray bars with values displayed on the right vertical axis show the percentage of patients
assessed with sensitive imaging techniques like CT, MRI, and PET (CT/MR/PET) as part of the diagnostic work-up. The years of diagnosis in the
calendar period 2005–2017 are shown on the horizontal axis. Patients diagnosed in 2018 were not fully registered at data cut-off.
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del17p, t(4;14), or t(14;16) with a cut-off of 10%. Patients
with AL amyloidosis, medullary compression syndrome,
peripheral neuropathy, or dialysis-dependent renal failure
at presentation were excluded. The incidence of MGUS-
like MM patients was age-adjusted to the EU 2013
population. Causes of diagnostic work-up were reviewed
by audit of medical records. Data were entered in a
Research Electronic Data Capture (REDcap) database and
merged with the baseline characteristics from DMMR.
At the time of data cut-off for this study (3rd April
2019), the DMMR included 5116 newly diagnosed mye-
loma patients (Fig. 1A). We found a significant increase in
the age-adjusted incidence of MM between 2005 and
2017 (p < 0.001; Fig. 1B). This increase was also present in
MGUS-like MM with an IgG M-protein ≤1.5 g/dl or an
IgA M-protein ≤1.0 g/dl with normal hemoglobin, crea-
tinine, and ionized calcium at diagnosis (p < 0.0001;
Fig. 1B). The increase in the incidence of MM correlated
significantly with a wider use of sensitive imaging tech-
niques in the diagnostic work-up, such as CT, PET-CT, or
MRI (r= 0.86; p= 0.0002; Supplementary Fig. 1). The
diagnostic sFLC ratio had a stronger correlation to the
bone marrow clonal plasma cell percentage compared to
the diagnostic M-protein concentrations (Supplementary
Figs. 2 and 3).
We identified 139 patients (5.5% of patients in the
DMMR with available sFLC results), with MGUS-like
MM. The clinical characteristics of these patients are
presented in Supplementary Table 1. Osteolytic lesions
were found in 23.9%. No patients had higher than 60%
bone marrow clonal plasma cell infiltration. The results of
FISH analysis were available in 51.1% of the patients.
High-risk cytogenetics were found in 12.7% of patients.
Hypogammaglobulinemia, elevated Beta-2-microglobulin
and elevated LDH were found in 52.9%, 34.5%, and 15.4%
of patients, respectively.
Causes of diagnostic work-up were available in all
patients but one (Supplementary Table 2). Eighty (58.0%)
patients were referred with symptoms, most frequently
bone pain and fatigue. Ninety-one (65.9%) patients were
referred with abnormal blood tests, most frequently the
presence of a serum M-protein. Fourteen (10.1%) patients
were referred with an abnormal skeletal imaging result.
Eight (5.8%) patients were referred because of a biopsy
finding. The number of patients without bone pain or
abnormal skeletal imaging results at referral was 92
(67.2%), of these 38 (41.8%) had bone lesions. Fifty-eight
patients (42.0%) did not have any symptoms at referral; of
these 27 (29.5%) had bone lesions.
Data from the DMMR show an increase in the age-
adjusted incidence of MM over the years that correlates
with the wider use of sensitive imaging techniques. The
incidence of MGUS-like MM has also increased from
0.12/100.000 in the calendar period 2005–2007 to 0.74/
100.000 in the calendar period 2015–2017. In daily
practice, the decision whether a bone marrow biopsy and
sensitive imaging techniques should be performed in such
patients is difficult, and there is an inherent risk of mis-
diagnosing MM as MGUS. In our population-based reg-
istry, 5.5% of MM patients had MGUS-like MM.
Although bone marrow sampling did not have therapeutic
implications in our population, our findings indicate that
even in patients referred with low M-protein concentra-
tions, normal sFLC ratio and normal levels of hemoglobin,
creatinine and ionized calcium, careful evaluation of
symptoms and sensitive imaging techniques should be
considered.
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